Inhibrx Stock Insiders

INBX -  USA Stock  

USD 40.53  0.71  1.78%

Break down of Inhibrx management performance can provide insight into the company performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Inhibrx future performance.
Please see Risk vs Return Analysis.

Inhibrx Return on Sales

(5.47)Share
Symbol  INBX
Name  Inhibrx
TypeStock
Country   United States
Exchange  NASDAQ

Information on Inhibrx Leadership is currently not available.

If you believe this information is not accurate please let us know and we will check it out.

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity..

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  

Inhibrx Management Team Effectiveness

Inhibrx has return on total asset (ROA) of (58.63) % which means that it has lost $58.63 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (567.79) %, meaning that it created substantial loss on money invested by shareholders. Inhibrx management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. Return on Average Assets is likely to drop to -0.97 in 2021. Return on Average Equity is likely to drop to 7.06 in 2021. Inhibrx Total Assets are fairly stable at the moment as compared to the past year. Inhibrx reported Total Assets of 143.74 Million in 2020. Current Assets is likely to rise to about 142.6 M in 2021, whereas Assets Non Current are likely to drop slightly above 11.3 M in 2021.

Inhibrx Quarterly Total Assets

141.89 MillionShare
Weighted Average Shares is likely to drop to about 25.2 M in 2021. Weighted Average Shares Diluted is likely to drop to about 25.2 M in 2021

Inhibrx Workforce Comparison

Inhibrx is currently regarded as number one stock in number of employees category among related companies. The total workforce of Biotechnology industry is currently estimated at about 97.0. Inhibrx totals roughly 84.0 in number of employees claiming about 87% of stocks in Biotechnology industry.

Inhibrx Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Inhibrx insiders, such as employees or executives, is commonly permitted as long as it does not rely on Inhibrx's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Inhibrx insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Inhibrx Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Inhibrx Price Series Division is a division of Inhibrx price series and its benchmark/peer. View also all equity analysis or get more info about price series division math operators indicator.

About Inhibrx Management Performance

The success or failure of an entity such as Inhibrx often depends on how effective the management is. Inhibrx management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Inhibrx management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Inhibrx management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please read more on our stock advisor page.
Last ReportedProjected for 2021
Return on Average Assets(0.89) (0.97) 
Return on Average Equity 8.41  7.06 
Return on Invested Capital(2.28) (2.46) 
Return on Sales(5.07) (5.47) 
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Inhibrx, Inc. was founded in 2010 and is headquartered in La Jolla, California. Inhibrx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 84 people.
The data published in Inhibrx's official financial statements usually reflect Inhibrx's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Inhibrx. For example, before you start analyzing numbers published by Inhibrx accountants, it's critical to develop an understanding of what Inhibrx's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Inhibrx's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Inhibrx's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Inhibrx's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Inhibrx. Please utilize our Beneish M Score to check the likelihood of Inhibrx's management to manipulate its earnings.
Please see Risk vs Return Analysis. Note that the Inhibrx information on this page should be used as a complementary analysis to other Inhibrx's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Complementary Tools for Inhibrx Stock analysis

When running Inhibrx price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
The market value of Inhibrx is measured differently than its book value, which is the value of Inhibrx that is recorded on the company's balance sheet. Investors also form their own opinion of Inhibrx's value that differs from its market value or its book value, called intrinsic value, which is Inhibrx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inhibrx's market value can be influenced by many factors that don't directly affect Inhibrx underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inhibrx's value and its price as these two are different measures arrived at by different means. Investors typically determine Inhibrx value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inhibrx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.